GSK plc Sponsored ADR (GSK)
GSK going nowhere while key vaccines struggle, says US bank
GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception according to analysts at US bank Jefferies. Downgrading its investment rating to 'hold', Jefferies said that the spate of good news - favourable Zantac settlement, robust performance of Specialty, and pipeline successes – has been swamped by concerns about vaccines Shingrix (Shingles) and Arexvy (RSV).
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays
Barclays lowered the firm's price target on GSK to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group.
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
GSK plc (GSK) Q3 2024 Earnings Call Transcript
GSK plc (NYSE:GSK ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Jeff McLaughlin - IR Tony Wood - Chief Scientific Officer Conference Call Participants James Gordon - JPMorgan Kerry Holford - Berenberg Jo Walton - UBS Simon Baker - Redburn Atlantic Graham Parry - Bank of America Emmanuel Papadakis - Deutsche Bank Richard Parkes - BNP Paribas Peter Welford - Jefferies Operator Hello, everyone. Welcome to today's call and webcast.
GSK (GSK) Q3 Earnings Surpass Estimates
GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
GSK: Earnings Confirm It's On Track To Meet Guidance
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS growth of 14% exceeds it. While the numbers slumped in Q3 2024, this was expected, especially as reported earnings absorbed Zantac related payouts. They are unlikely to impact full year figures, however.
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy skidded.
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 billion.
GSK Stock Drops as UK Firm Posts Underwhelming Results
GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.
GSK cuts vaccine sales target on reduced demand
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
